Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISIS 183750 with Docetaxel/Prednisone in CRPC
NCT01234025Phase 2Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Nov 2010
- Primary completion
- May 2013
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 6
01
Overview
Phase 2, randomised, open-label trial of LY2275796 in prostate cancer (PCa) (4 arms), sponsored by Ionis Pharmaceuticals. Primary endpoint: Progression free survival. Started Nov 2010; status: completed.
02
Drugs
LY2275796
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT01234025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01234025.